Form 4: Recursion Pharmaceuticals CEO, Christopher Gibson, Reports Share Transactions

Christopher Gibson, CEO of Recursion Pharmaceuticals, reports the withholding of 26,023 shares for tax obligations and provides an update on his holdings of Class A and Class B common stock and stock options.

Summary

• Christopher Gibson, the CEO of Recursion Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The filing indicates that 26,023 shares of Class A Common Stock were withheld by the company to cover tax obligations related to the net settlement of restricted stock units at a price of $6.175 per share.
• Following this transaction, Gibson directly owns 736,633 shares of Class A Common Stock.
• The filing also details Gibson's holdings of Class B Common Stock, which are convertible to Class A Common Stock, and various stock options with different exercise prices and vesting schedules.
• Gibson's indirect holdings include shares held through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, and while the share withholding is a transaction, it is for tax purposes and does not indicate a negative sentiment. The continued ownership of a large number of shares and options is a positive sign.

Positives

• The filing provides transparency into the CEO's holdings and transactions.
• The CEO's continued ownership of a significant number of shares and options demonstrates his vested interest in the company's success.

Risks

• The sale of shares to cover tax obligations could be perceived negatively by some investors, although it is a common practice.
• The complex structure of holdings through various entities could make it difficult for some investors to fully understand the CEO's total stake.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders and are common across all publicly traded companies.

Comparison to Industry Standards

• The reporting of insider transactions via Form 4 is a standard practice for all publicly traded companies in the US, including biotechnology companies like Recursion Pharmaceuticals.
• The level of detail provided in this Form 4 is consistent with what is expected for executive officers, including the reporting of direct and indirect holdings, as well as stock options.
• Comparable companies in the biotechnology sector, such as BioNTech or Moderna, also have their executives file similar Form 4 reports when they engage in transactions involving their company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the CEO's transactions and holdings.
• The withholding of shares for tax obligations has a minor impact on the total number of shares outstanding.

Key Dates

Keywords

Recursion Pharmaceuticals, Christopher Gibson, Form 4, Beneficial Ownership, Stock Options, Class A Common Stock, Class B Common Stock, Share Transactions, LAHWRAN-3 LLC, LAHWRAN-4 LLC, Gibson Family Trust